UNIQUE PROBIOTIC STRAIN FOR THE MANAGEMENT OF PRE-DIABETES CONDITION &ASSOCIATED CARDIOVASCULAR RISKS
Bifidobacterium psychraerophilum Q5 (DSM 33131)
Recommended dosage: 1 billion cells per day (better combined with not less than 150mg of mulberry leaves)
Scientific Data
Probiotics were investigated in an in vitro diabetic model, with regard to hyperglycemia, insulin resistance, hypercholesterolemia and dyslipidemias. In particular, the following were analyzed:
- analysis of cytotoxicity and production of reactive oxygen species
- the main markers involved in glucose metabolism (such as AKT, GLUT4 and PGC-1)
- cardiovascular risk analysis on endothelial and cardiac cell co-culture model
To better understand the effect, after the first screening the most effective combinations were studied in a complete cardio-metabolic model, including the intestinal passage up to the cardiovascular risk control:
- evaluation of liver damage
- analysis of free cholesterol levels
- lipids accumulation and circulating LDL
- inflammatory picture and pro-inflammatory cytokines analysis
Results
Metabolic syndrome and hypergliceamia are risk factors not only for diabetes but also for cardiovascular diseases. After assessing the probiotics in the diabetic model, we further investigated them for cardiovascular risk prevention. Here, Bifido Q5 showed by lead the most interesting properties when combined with white-mulberry leaves extract.
PROBIOTIC EFFECT VARIATION VS REFERENCE
Key Points
- Exclusive Next Generation Probiotic strain Bifido Q5
- Demonstrated effective and synergically combined with Reducose® (white-mulberry leaves extract patented ingredient, clinically studied for the support of healthy blood sugar response) [clinical effective dosage = 200mg per serving]
- Studied in a pre-clinical in vitro human model of gut-heart axis under diabetic condition
- Scientific communication under submission
- Clinical trial protocol submitted to ethical committee for trial approval and starts in 2023
- Without food allergens Reg. 1169/2011
